Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.

José M Rodriguez-Valadez Malak Tahsin Umesh Masharani Meyeon Park M G Myriam Hunink Joseph Yeboah Lihua LiEllerie WeberAsem BerkalievaLuuk AvezaatWendy B Max Kirsten E Fleischmann Bart S Ferket

Published in: Journal of the American Heart Association (2024)

We confirmed increased efficacy findings for major adverse cardiovascular events with reduction in glycated hemoglobin for GLP1-RAs. Further research is needed on the potential loss of cardiovascular benefits with increased weight loss and hematocrit for SGLT2i.

Keyphrases

cardiovascular events
cardiovascular disease
weight loss
coronary artery disease
type diabetes
glycemic control
bariatric surgery
human health
emergency department
roux en y gastric bypass
risk assessment
adipose tissue
combination therapy
gastric bypass
red blood cell
skeletal muscle
wild type
weight gain